Listen: Messy PBM conflicts, debatable vaccines, & the future of flu season
Who's watching the drug price watchmen? Are RSV vaccines too expensive? And is it finally time for Novavax to shine? Find out on the new episode of "The Readout LOUD."
Who’s watching the drug price watchmen? Are RSV vaccines too expensive? And is it finally time for Novavax to shine?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Bob Herman joins us to explain his year-long investigation into some brazen conflicts of interest in the world of prescription drug pricing. Then, STAT’s Helen Branswell calls in to walk us through a news-packed week for vaccines, including weighty decisions for Covid-19 and RSV.
What's Your Reaction?
